NCT05196399View on ClinicalTrials.gov

Bioequivalence Study of Different Aprocitentan Tablet Formulations

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

February 2, 2022

Primary Completion Date

March 27, 2022

Study Completion Date

April 7, 2022

Conditions
Healthy Subjects
Interventions
DRUG

Aprocitentan (Formulation A)

A single oral dose of 25 mg.

DRUG

Aprocitentan (Formulation B)

A single oral dose of 25 mg.

Trial Locations (1)

323 00

CEPHA s.r.o., Pilsen

Sponsors
All Listed Sponsors
lead

Idorsia Pharmaceuticals Ltd.

INDUSTRY